Trial Profile

The Effect of the Alpha-7 Nicotinic AChR Agonist GTS-21 on Inflammation and End-Organ Dysfunction During Human Endotoxemia.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 09 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs GTS 21 (Primary) ; Escherichia coli lipopolysaccharide; Lipopolysaccharide
Indications Alzheimer's disease; Attention-deficit hyperactivity disorder; Cognition disorders
Focus Pharmacodynamics

Most Recent Events

04 Nov 2010 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.
04 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
23 Nov 2008 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com